Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neoplasm Metastasis 2Sarcoma 1Rhabdomyosarcoma 1Neoplasms 1Medulloblastoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Temozolomide 15Filgrastim 13Cyclophosphamide 9Carboplatin 9Granulocyte Colony-Stimulating Factor 7Etoposide 7Thiotepa 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Vorinostat 4Busulfan 4sonidegib 3ribociclib 3Vincristine 3Topotecan 3O(6)-benzylguanine 3Magnetic Resonance Spectroscopy 3Irinotecan 3Automobiles 3veliparib 2sargramostim 2pembrolizumab 2fludarabine 2etoposide phosphate 2Valproic Acid 2Thalidomide 2Surgical Procedures, Operative 2Stem Cell Transplantation 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Medulloblastoma × LY2940680 × Clear all
NCT01697514 2013-08-27

A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma

Eli Lilly and Company

Phase 1 Withdrawn
CNSSarcoma

Medulloblastoma, Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡